Exicure, Inc. (NASDAQ:XCUR) Short Interest Up 58.5% in March

Exicure, Inc. (NASDAQ:XCUR) saw a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 44,700 shares, an increase of 58.5% from the February 28th total of 28,200 shares. Currently, 1.8% of the shares of the stock are sold short. Based on an average trading volume of 76,100 shares, the days-to-cover ratio is presently 0.6 days.

Hedge Funds Weigh In On Exicure

An institutional investor recently bought a new position in Exicure stock. Geode Capital Management LLC purchased a new stake in Exicure, Inc. (NASDAQ:XCUR) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 12,645 shares of the company’s stock, valued at approximately $173,000. Geode Capital Management LLC owned about 0.48% of Exicure as of its most recent filing with the SEC. Institutional investors own 42.82% of the company’s stock.

Exicure Stock Down 0.1 %

Shares of NASDAQ:XCUR opened at $13.99 on Friday. The company has a market capitalization of $36.46 million, a P/E ratio of -6.76 and a beta of 3.84. Exicure has a 52-week low of $1.44 and a 52-week high of $36.00. The stock’s fifty day simple moving average is $11.08 and its 200-day simple moving average is $9.94.

Exicure (NASDAQ:XCUR) last released its earnings results on Tuesday, March 18th. The company reported ($3.39) earnings per share (EPS) for the quarter.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.